An automated 24-hour CAR-T manufacturing process

With the therapeutic efficacy of current commercialized CAR-T cell therapies having been firmly established, attention has shifted to the lengthy and complex manufacturing process that currently limits their usage by driving up the cost of therapy while also prolonging critical delivery timelines to patients. Early pre-clinical studies indicate promise for a shorter manufacturing process that significantly decreases the manufacturing timeline to a 24-hour process. Innovative tools that allow for closure of the manufacturing process and minimization of manual touchpoints have helped streamline and eliminate manufacturing failures. Advancements in digital integration tools have also contributed to achievement of a more standardized manufacturing approach.

This webinar will provide viewers with:

• An overview and general protocol of a significantly shortened manufacturing process timeline leveraging the new CTS detachable dynabeads CD3/CD28
• Detailed results of a new viral-based 24-hour CAR-T manufacturing process
• Demonstration of digital and physical integration of multiple Thermo Fisher technologies using the new CTS Cellmation software
• Discussion of the current challenges facing autologous CAR-T manufacturers and patients
• Strategies to combat the prohibitive cost of these therapies, decrease the vein-to-vein timelines, and incorporate recent learnings broadly across the field

Mina Ahmadi

R&D Lead Scientist, Cell and Gene Therapy at Thermo Fisher Scientific

Mina Ahmadi is a R&D lead scientist at Thermo Fisher Scientific where she focuses on developing end-to-end closed and automated viral and non-viral cell therapy workflows. Dr. Ahmadi received her Ph.D. in Molecular Genetics from McGill University, Canada. After her Ph.D., she joined as Postdoctoral Fellow at Department of Pharmacy, University of Toronto, Canada.

Fabio Fachin

Head of Cell Therapy Process Development, Automation & Digital Technologies at Takeda

Fabio Fachin, PhD, is the Head of Cell Therapy Process Development, Automation and Digital Technologies at Takeda, a company focusing on off-the-shelf, allogeneic cell therapies targeting both solid tumors and hematological malignancies. Prior to Takeda, Dr. Fachin was at Novartis where he contributed to the development of Kymriah, and at Torque Therapeutics where he was VP of Cell Therapy Development and Manufacturing. Dr. Fachin holds a PhD in Aerospace Engineering from the Massachusetts Institute of Technology, and a Post-Doctoral Fellowship from Harvard Medical School. His early career was in the aerospace sector, developing micro-technologies for aircraft and satellite guidance.

Watch now

SPEAKERS

Mina Ahmadi

R&D Lead Scientist, Cell and Gene Therapy at Thermo Fisher Scientific

Fabio Fachin

Head of Cell Therapy Process Development, Automation & Digital Technologies at Takeda

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 56

Days

Register

Specifications don’t tell the whole story: how to choose GMP process and QC equipment

M Kay Bates, W Marin, K Whitlatch

18 June

in 47

Days

Register

Quadplex dPCR as a tool to analyze genome integrity and heterogeneity in gene therapy drug products

Ryan Massopust

11 June

in 40

Days

Register

Precision in production: optimizing monitoring and quality control for high-value plasmids

Oleksandr Karpenko

6 June

in 35

Days

Register

Advancing cell therapy: innovations in polymer-based encapsulation and delivery

Y Brudno, O Veiseh, M Delic-Schlumbohm et al.

5 June

in 34

Days

Register